November 12, 2024
ISOFOL MEDICAL AB (PUBL) PUBLISHES INTERIM REPORT
JANUARY-SEPTEMBER, 2024
About Isofol
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- January 13, 2025 - January 16, 2025
JP Morgan, USA
Isofol will be present during the JP Morgan Healthcare Conference in San Francisco. John Proffett, Business Development Lead, will be present on-site. Reach out to him if you would like to meet! - February 19, 2025 - February 19, 2025
Year-end report 2024 - April 09, 2025 - April 11, 2025
Annual report 2024, published in week 15, April 2025
Media – Lates pressreleases
Isofol and its partner Solasia plan to expand the upcoming clinical trial of arfolitixorin to Japan
GOTHENBURG, Sweden, December 18, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that its partner Solasia Pharma K.K. (Solasia) has made…
Isofol announces that an investigator-initiated study of arfolitixorin has been published in BJC Reports
GOTHENBURG, Sweden, November 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the investigator-initiated Modelle study, evaluating the effect of…
Isofol provides an operational update during investor meeting
GOTHENBURG, Sweden, November 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), will provide an operational update during today’s investor meeting. The company…
INVESTORS – latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
